CXCL8 and cancer: Slight variations in use of adjuvants polybrene and IL-8, and increased AdCre dose in group 3 were used to adapt to findings in the 1st cohort (e.g., histopathological lack of invasive cancer in group 1, inflammatory reactions observed in group 1&2).